NASDAQ:CLLS
Cellectis S.A. Stock News
$2.99
-0.0499 (-1.64%)
At Close: May 17, 2024
Cellectis: Monthly Information on Share Capital and Company Voting Rights
09:30pm, Friday, 06'th Mar 2020
Monthly information on share capital and company voting rights.
Cellectis SA (CLLS) Received its Third Buy in a Row
08:01pm, Thursday, 05'th Mar 2020
After William Blair and BTIG gave Cellectis SA (NASDAQ: CLLS) a Buy rating last month, the company received another Buy, this time from JonesTrading.
Cellectis SA (CLLS) Received its Third Buy in a Row
08:01pm, Thursday, 05'th Mar 2020
After William Blair and BTIG gave Cellectis SA (NASDAQ: CLLS) a Buy rating last month, the company received another Buy,
Cellectis SA (CLLS) Receives a Buy from William Blair
07:45pm, Thursday, 05'th Mar 2020
William Blair analyst Raju Prasad maintained a Buy rating on Cellectis SA (CLLS) today. The company's shares closed last Monday at $15.69. According to
Cellectis SA (CLLS) Receives a Buy from William Blair
07:45pm, Thursday, 05'th Mar 2020
William Blair analyst Raju Prasad maintained a Buy rating on Cellectis SA (CLLS – Research Report) today. The company’s shares
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results
09:30pm, Wednesday, 04'th Mar 2020
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results
Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products
09:05pm, Wednesday, 04'th Mar 2020
Cellectis and Servier Execute the Amendment Confirming the Expansion of their Collaboration on UCART19 Products
CRISPR Therapeutics: A Review Of Its Clinical Pipeline And Progress
04:13pm, Sunday, 01'st Mar 2020
CRISPR Therapeutics is a gene-editing company focused on using CRISPR/Cas 9 in therapeutics areas such as hemoglobinopathies, immuno-oncology, regenerative medi
Analyzing Iovance Biotherapeutics (NASDAQ:IOVA) & BioNTech (NASDAQ:BNTX)
06:46am, Thursday, 27'th Feb 2020
Iovance Biotherapeutics (NASDAQ:IOVA) and BioNTech (NASDAQ:BNTX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of the
Precision BioSciences: Consider Taking Up A Small Position
04:26pm, Monday, 24'th Feb 2020
Precision BioSciences is advancing its allogeneic CAR Ts based on its ARCUS gene-editing platform. Interim data updates of its lead program was disappointing du
Ziopharm Stands Out, But Still Riskier Than Cellectis
02:03pm, Friday, 31'st Jan 2020
Ziopharm’s TCR approach targets solid tumors by recognizing neoantigens unique to each patient's cancer. The Sleeping Beauty solid tumor treatment is still auto
Financial Survey: Cellectis (NASDAQ:CLLS) vs. Translate Bio (NASDAQ:TBIO)
07:50am, Thursday, 30'th Jan 2020
Cellectis (NASDAQ:CLLS) and Translate Bio (NASDAQ:TBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profita
Imagine Owning Cellectis (EPA:ALCLS) And Wondering If The 43% Share Price Slide Is Justified
04:01am, Tuesday, 28'th Jan 2020
Cellectis S.A. (EPA:ALCLS) shareholders will doubtless be very grateful to see the share price up 47% in the last...
2 Top Biotech Stocks to Buy Right Now
02:25pm, Thursday, 23'rd Jan 2020
These two companies are pushing the envelope of immunotherapies by developing unique cell types. Each has promising results for investors to consider.
Cellectis: Pioneer In Allogeneic CAR T, But Hampered By Slow Progress
08:07pm, Tuesday, 21'st Jan 2020
Cellectis is pioneering development of allogeneic CAR Ts which hold several advantages over current generations of autologus CAR Ts. Despite its early work, Cel
